October 1987

Regression of Melanoma Nodules in a Patient Treated With Ranitidine

Author Affiliations

From the Department of Medicine, Medical College of Virginia, Richmond (Dr Smith); the National Cancer Institute, Biological Response Modifiers Program, Frederick, Md (Dr Clark); and the Department of Surgery, University of Cincinnati Medical Center (Dr Popp).

Arch Intern Med. 1987;147(10):1815. doi:10.1001/archinte.1987.00370100129020

• Human malignant melanoma may regress spontaneously or with immunotherapy, such as Calmette-Guerin bacillus, interferon alfa, interleukin-2, and interleukin-2 plus lymphokine-activated killer cells. Histamine type 2 receptor antagonists can modulate immune function by inhibiting suppressor T-cell induction and activity, and melanoma regressions have been reported after the use of cimetidine with coumarin or interferon alfa. This article describes the complete regression of melanoma nodules in a patient treated with ranitidine hydrochloride, another histamine type 2—receptor antagonist. Ranitidine and cimetidine should be considered to be possibly active immunotherapeutic agents in the design and evaluation of clinical trials.

(Arch Intern Med 1987;147:1815-1816)